Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 20, Issue 4, 1997, Pages 383-386

  Colleoni, Marco ^a   Graiff, C ^a   Vicario, G ^a   Nelli, P ^a   Sgarbossa, G ^a   Pancheri, F ^a   Manente, P ^a  

^a City Hospital   (Italy)

Author keywords

Chemotherapy; Estramustine; Etoposide; Prostate cancer; Vinorelbine

Indexed keywords

ETOPOSIDE; NAVELBINE;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOSKELETON; DOSE RESPONSE; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; MALE; MICROTUBULE; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PROSTATE CANCER; REMISSION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; ESTRAMUSTINE; ETOPOSIDE; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REMISSION INDUCTION; VINBLASTINE;

EID: 0030835839     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199708000-00013     Document Type: Article

References (22)

1. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993;71:1098-1109.
2. Jones WG. The role of chemotherapy in refractory prostate cancer. Curr Opin Urol 1991;1:21-4.
3. Tannock IF. Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? J Clin Oncol 1985;3:1013-21.
4. Pienta KJ, Partin AW, Coffey DS. Cancer as a disease of DNA organization and dynamic cell structure. Cancer Res 1989;49: 2525-30.
5. Nelson WG, Pienta JJ, Barrack ER, et al. The role of the nuclear matrix in the organization and function of DNA. Ann Rev Biophys Chem 1986;15:457-75.
6. Getzeberg RH, Pienta KJ, Coffey DS. The tissue matrix: cell dynamics and hormone action. Endocrine Rev 1990;11:399-422.
7. Pienta KJ, Getzenberg RH, Coffey DS. Cell structure and DNA organization. Crit Rev E Gene Expression 1991;14:355-85.
8. Pienta KJ, Redman B, Hussain M, et al. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 1994;10:2005-12.
9. Seidman A, Scher HI, Petrylak D, et al. Estramustine and vinblastine: use of prostate-specific antigen as a clinical trial end point for hormone-refractory prostate cancer. J Urol 1992;147: 931-4.
10. Hudes GR, Greenberg R, Krigel RL, et al. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol 1992;10: 1754-61.
11. Fields S, Burris III H, Wilding G, et al. Evaluating the role of navelbine in hormone-refractory prostate cancer (HRPC): a clinical benefit model. Proc Am Clin Oncol 1994;13:235.
12. Gehan EA. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 1961;13:346-53.
13. Tew KD, Stearns ME. Hormone-independent, non-alkylating mechanism of cytotoxicity for estramustine. Urol Res 1987;15: 155-60.
14. Wallin M, Deinum J, Friden B. Interaction of estramustine phosphate with microtubule-associated proteins. Febs Lett 1985;179:289-93.
15. Soloway MS, DeKernion JB, Gibbons RP, et al. Comparison of estramustine phosphate and vincristine alone or in combination for patients with advanced, hormone-refractory, previously irradiated carcinoma of the prostate. J Urol 1981;125: 664-7.
16. Hartley-Asp B, Kruse E. Nuclear protein matrix as a target for estramustine-induced cell death. Prostate 1986;9:387-95.
17. Hussain MH, Pienta KJ, Redman BG et al. Oral etoposide in the treatment of hormone-refractory prostate cancer. Cancer 1994;74:100-3.
18. Walther PJ, Williams SD, Troner M, et al. Phase II study of etoposide for carcinoma of the prostate. Cancer Treat Rep 1986;70:771-2.
19. Scher HI, Yagoda A. Clinical trials in prostatic cancer: methodologies and controversies. In: Bruce AW, Trachtenberg J, eds. Adenocarcinoma of the prostate. London: Springer-Verlag, 1987:197-219.
20. Scher HI, Curley T, Geller N, et al. Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease. J Clin Oncol 1990;8:1830-8.
21. Gerber GS, Chodak GW. Prostate specific antigen for assessing response to ketoconazole and prednisone in patients with hormone refractory prostate cancer. J Urol 1990;144:1177-81.
22. Amato RJ, Logothetis CJ, Dexeus FH, et al. Preliminary results of phase II trial of estramustine and vinblastine for patients with hormone-refractory prostate cancer. Proc Am Soc Cancer Res 1991;32:186.